CTLA4 and ovarian carcinoma: A phase II trial of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) in 17 patients with rare non-epithelial ovarian cancers reported a 25% ORR in granulosa cell tumors, with one CR and one PR lasting over four Years, And a 50% clinical benefit rate [52].